Innate Pharma (IPHA)
Kepler Capital analyst Damien Choplain upgraded Innate Pharma to Buy on September 22 and set a price target of EUR6.00. The company’s shares closed last Thursday at $3.77, close to its 52-week low of $3.30.
According to TipRanks.com, Choplain is ranked #2302 out of 6915 analysts.
Innate Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $9.78, representing a 156.0% upside. In a report issued on September 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
Crossject SA (CRJTF)
Kepler Capital analyst Paul de Froment maintained a Hold rating on Crossject SA on September 21 and set a price target of EUR2.20. The company’s shares closed last Monday at $3.75, equals to its 52-week high of $3.75.
According to TipRanks.com, Froment is ranked #1634 out of 6915 analysts.
The the analyst consensus on Crossject SA is currently a Hold rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.